Company intelligence / Profile preview
Haoma Medica
London, England, United Kingdomhaomamedica.com ↗
- Ownership
- Private
- Employees
- ~6
- Development stage
- Phase 2
01
Overview
Haoma Medica has developed NaQuinate, a novel small molecule compound for osteoporosis and osteopenia. The first-in-human Phase I study demonstrated safety, tolerability, and pharmacokinetics in healthy volunteers. The compound works by regulating both bone formation and resorption with the potential for long-term use due to its natural occurrence in the body. No efficacy data from later-stage trials are yet available.
- Therapeutic areas
- HematologyEndocrinology
- Modalities
- Small molecules (NaQuinate)
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Haoma Medica.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Haoma Medica.